AP NEWS

Sensei Biotherapeutics to Present at BIO CEO & Investor Conference

February 5, 2019

GAITHERSBURG, Md.--(BUSINESS WIRE)--Feb 5, 2019--Sensei Biotherapeutics, Inc., a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies, announced today that John Celebi, President and Chief Executive Officer of Sensei Biotherapeutics, will present a company overview at the BIO CEO & Investor Conference on Monday, February 11, 2019, at 3:45 p.m. ET in New York, NY.

About Sensei Biotherapeutics Sensei Biotherapeutics is a clinical-stage biopharmaceutical company developing precision immuno-oncology therapies to transform the cancer treatment landscape. The company is using its proprietary drug discovery platform, called SPIRIT, to discover and develop both vaccines and T-cell therapies, including SNS-301, its clinical stage cancer vaccine, and SNS-723, its cell therapy program in preclinical development, for solid tumors and hematological cancers. These programs target ASPH, a novel embryonic antigen. Sensei’s precision medicine approach in immuno-oncology includes the use of companion diagnostics to select patients who are most likely to respond to its tumor-specific antigen therapies. Sensei Biotherapeutics is located in Gaithersburg, MD. For more information, please visit www.senseibio.com.

View source version on businesswire.com:https://www.businesswire.com/news/home/20190205005225/en/

CONTACT: Media Contact:

Kathryn Morris

The Yates Network

914-204-6412

kathryn@theyatesnetwork.com

Investor Contact:

Julie Seidel

Stern Investor Relations, Inc.

212-362-1200

julie@sternir.com

KEYWORD: UNITED STATES NORTH AMERICA MARYLAND NEW YORK

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS ONCOLOGY PHARMACEUTICAL

SOURCE: Sensei Biotherapeutics

Copyright Business Wire 2019.

PUB: 02/05/2019 08:30 AM/DISC: 02/05/2019 08:30 AM

http://www.businesswire.com/news/home/20190205005225/en

AP RADIO
Update hourly